![]() Clopidogrel (see drug link for specific age and indication-related dosages).In pts with true ASA allergies, substitute Clopidogrel.Should be used in all ACS unless contraindicated (eg Anaphylaxis).Medical management vs cath determined by level of risk for future cardiovascular events.Dual antiplatelet therapy and antithrombotic therapy is mainstay of treatment.High-risk findings on noninvasive stress testing.New or presumably new ST-segment depression.Recurrent angina/ischemia with or with out symptoms of CHF.Esophageal perforation (Boerhhaave's syndrome).More likely to report central chest painįactors associated with delayed presentation ĭifferential Diagnosis Chest pain Critical. ![]() More likely to report fatigue, dyspnea, indigestion, nausea or vomiting, palpitations, or weakness, although some studies have found fewer differences in presentation.Less likely to receive timely reperfusion therapy.Less likely to undergo cardiac catheterization.Less likely to be treated with guideline-directed medical therapies.Chest pain associated with nausea/vomitingĬlinical factors that decrease likelihood of ACS/AMI:.Chest pain radiating to both arms > R arm > L arm.Type 5: Myocardial Infarction Related to CABG ProcedureĬlinical factors that increase likelihood of ACS/AMI:.Type 4: Myocardial Infarction Associated With Revascularization Procedure.Sudden cardiac death with symptoms suggestive of myocardial ischaemia without elevated biomarkers.Type 3: Cardiac Death Due to Myocardial Infarction.coronary spasm, embolism, low or high blood pressures, anemia, or arrhythmias) Condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand (e.g.Type 2: Myocardial Infarction Secondary to an Ischemic Imbalance.Atherosclerotic plaque rupture or intraluminal thrombus in one or more of the coronary arteries.Type 1: Spontaneous Myocardial Infarction.NSTEMI includes Type 2 -Type 5 biomarker elevations.Association between quantity of troponin and risk of death.Age >65 with MI and anemia had 33% reduction in 30 day mort if transfused to keep HCT >30.5% of NSTEMI will develop Cardiogenic Shock (60% mortality).33% with confirmed MI have no chest pain on presentation (especially older, female, DM, CHF).5.4 Unstable Angina - NSTEMI Guidelines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |